| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $215,240 and 6, calls, for a total amount of $237,164.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $47.0 for Bristol-Myers Squibb over the last 3 months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bristol-Myers Squibb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bristol-Myers Squibb's significant trades, within a strike price range of $35.0 to $47.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | PUT | SWEEP | BEARISH | 09/20/24 | $4.75 | $4.65 | $4.75 | $47.00 | $117.8K | 1.6K | 249 |
| BMY | PUT | SWEEP | BEARISH | 09/20/24 | $4.8 | $4.7 | $4.8 | $47.00 | $97.4K | 1.6K | 453 |
| BMY | CALL | SWEEP | BULLISH | 08/16/24 | $1.75 | $1.5 | $1.56 | $44.00 | $59.9K | 804 | 387 |
| BMY | CALL | TRADE | BEARISH | 03/21/25 | $5.7 | $4.3 | $4.5 | $42.00 | $39.6K | 0 | 343 |
| BMY | CALL | TRADE | BEARISH | 03/21/25 | $5.75 | $4.25 | $4.5 | $42.00 | $39.6K | 0 | 343 |
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $45.5.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with Benzinga Pro for real-time alerts.
Posted In: BMY
